These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28185625)

  • 1. Impact of Erythropoiesis-Stimulating Agents on Behavioral Measures in Children Born Preterm.
    Lowe JR; Rieger RE; Moss NC; Yeo RA; Winter S; Patel S; Phillips J; Campbell R; Baker S; Gonzales S; Ohls RK
    J Pediatr; 2017 May; 184():75-80.e1. PubMed ID: 28185625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin.
    Ohls RK; Cannon DC; Phillips J; Caprihan A; Patel S; Winter S; Steffen M; Yeo RA; Campbell R; Wiedmeier S; Baker S; Gonzales S; Lowe J
    Pediatrics; 2016 Mar; 137(3):e20153859. PubMed ID: 26908704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Assessment of Preterm Infants Treated with Erythropoiesis Stimulating Agents.
    Ohls RK; Lowe J; Yeo RA; Patel S; Winter S; Campbell RA; Baker S; Phillips J
    Curr Pediatr Rev; 2023; 19(4):417-424. PubMed ID: 36537596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo.
    Ohls RK; Kamath-Rayne BD; Christensen RD; Wiedmeier SE; Rosenberg A; Fuller J; Lacy CB; Roohi M; Lambert DK; Burnett JJ; Pruckler B; Peceny H; Cannon DC; Lowe JR
    Pediatrics; 2014 Jun; 133(6):1023-30. PubMed ID: 24819566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates.
    Messier AM; Ohls RK
    Curr Opin Pediatr; 2014 Apr; 26(2):139-45. PubMed ID: 24535496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darbepoetin Administration in Term and Preterm Neonates.
    Patel S; Ohls RK
    Clin Perinatol; 2015 Sep; 42(3):557-66. PubMed ID: 26250917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroimaging in former preterm children who received erythropoiesis stimulating agents.
    Phillips J; Yeo RA; Caprihan A; Cannon DC; Patel S; Winter S; Steffen M; Campbell R; Wiedmeier S; Baker S; Gonzales S; Lowe J; Ohls RK
    Pediatr Res; 2017 Oct; 82(4):685-690. PubMed ID: 28553989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term effect of erythropoiesis stimulating agents given to preterm infants: a proton magnetic resonance spectroscopy study on neurometabolites in early childhood.
    Gasparovic C; Caprihan A; Yeo RA; Phillips J; Lowe JR; Campbell R; Ohls RK
    Pediatr Radiol; 2018 Mar; 48(3):374-382. PubMed ID: 29335880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection.
    Maxwell JR; Ohls RK
    Neoreviews; 2019 Nov; 20(11):e622-e635. PubMed ID: 31676737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact.
    Kiss Z; Elliott S; Jedynasty K; Tesar V; Szegedi J
    Eur J Clin Pharmacol; 2010 Apr; 66(4):331-40. PubMed ID: 20127232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of blood transfusions on cognitive development in very low birth weight infants.
    Shah P; Cannon DC; Lowe JR; Phillips J; Christensen RD; Kamath-Rayne B; Rosenberg A; Wiedmeier S; Patel S; Winter S; Baker S; Ohls RK
    J Perinatol; 2021 Jun; 41(6):1412-1418. PubMed ID: 33911186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shift from darbepoetin-α to continuous erythropoietin receptor activator decreases serum aluminium concentration in patients on hemodialysis.
    Liu WS; Chan HL; Lai YT; Yang YH; Teng HW; Liu CK; Li SY; Yang CY; Liu TY; Lin CC
    Environ Toxicol Pharmacol; 2016 Jul; 45():108-14. PubMed ID: 27267426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial.
    Natalucci G; Latal B; Koller B; Rüegger C; Sick B; Held L; Bucher HU; Fauchère JC;
    JAMA; 2016 May; 315(19):2079-85. PubMed ID: 27187300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents: development, detection and dangers.
    Franz SE
    Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.
    Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M
    JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.